ScholarLens Back to search
2004•Adelaide Research & Scholarship (AR&S) (University of Adelaide)Requires access

Two decades of progress in treating chemotherapy induced emesis

Ian Olver

Open publisher page 3 citations

Abstract

Nausea and vomiting have been listed by patients as the most distressing side effects of chemotherapy. There are three phases of emesis associated with chemotherapy. The introduction of 5HT3 receptor antagonists revolutionised the treatment of acute chemotherapy induced emesis but had only minor impact on delayed emesis. Aprepitant, a neurokinin 1 receptor antagonist has improved the control of acute emesis when added to a 5HT3 antagonist and dexamethasone and has made a major advance in the control of delayed emesis when continued for a further two days in combination with dexamethasone. This control of nausea and vomiting associated with chemotherapy has translated into improved quality of life of the patients receiving chemotherapy. (non- author abstract)

About this research paper

What this paper is about

Nausea and vomiting have been listed by patients as the most distressing side effects of chemotherapy. There are three phases of emesis associated with chemotherapy. The introduction of 5HT3 receptor antagonists revolutionised the treatment of acute chemotherapy induced emesis but had only minor impact on delayed emesis. Aprepitant, a neurokinin 1 receptor antagonist has improved the control of acute emesis when added to a 5HT3 antagonist and dexamethasone and has made a major advance in the control of delayed emesis when continued for a further two days in combination with dexamethasone. This control of nausea and vomiting associated with chemotherapy has translated into improved quality of life of the patients receiving chemotherapy. (non- author abstract)

Why it matters

OpenAlex reports 3 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Nausea and vomiting have been listed by patients as the most distressing side effects of chemotherapy. There are three phases of emesis associated with chemotherapy. The introduction of 5HT3 receptor antagonists revolutionised the treatment of acute chemotherapy induced emesis but had only minor impact on delayed emesis. Aprepitant, a neurokinin 1 receptor antagonist has improved the control of acute emesis when added to a 5HT3 antagonist and dexamethasone and has made a major advance in the control of delayed emesis when continued for a further two days in combination with dexamethasone. This control of nausea and vomiting associated with chemotherapy has translated into improved quality of life of the patients receiving chemotherapy. (non- author abstract)

Key concepts: Aprepitant, Vomiting, Nausea, Chemotherapy, Medicine, Dexamethasone, NK1 receptor antagonist, Chemotherapy-induced nausea and vomiting

Back to paper searchBrowse research topicsOriginal source
Two decades of progress in treating chemotherapy induced emesis — Research Paper | ScholarLens